Table 1 Characteristics of the patients with (n = 13) and without (n = 231) VD intoxication.
From: Vitamin D intoxication in patients with cystic fibrosis: report of a single-center cohort
No VD intoxication (n = 231) | VD intoxication (n = 13) | p-value | |
|---|---|---|---|
Age, years Median (IQR) | 23 (13–34) | 20 (9–33) | 0.41 |
M/F, n | 115/116 | 6/7 | 0.99 |
Paediatric status, n (%) | 74 (32.03) | 5 (38.46) | 0.76 |
F508del/F508del, n (%) | 92 (39.83) | 10 (76.92) | 0.01 |
ppFEV1, % Median (IQR) | 86 (63–104) (n = 205) | 81 (73–94) (n = 9) | 0.77 |
ppFVC, % Median (IQR) | 94 (82–107) (n = 205) | 112 (87–114) (n = 9) | 0.10 |
ACFLD, n (%) | 25 (12.20) (n = 205) | 0 (0) (n = 9) | 0.60 |
Weight, z-score Median (IQR) | − 0.48 (− 1.25–0.36) | − 0.30 (− 1.35–0.05) | 0.99 |
Height, z-score Median (IQR) | − 0.64 (− 1.30–0.16) | − 0.10 (− 1.35–0.20) | 0.61 |
BMI, z-score Median (IQR) | − 0.2 (− 1.00–0.57) | − 0.10 (− 0.85–0.10) | 0.62 |
Insulin use, n (%) | 39 (16.88) | 2 (15.38) | 0.99 |
Pseudomonas chronic infection, n (%) | 54 (23.89) (n = 226) | 5 (41.67) (n = 12) | 0.17 |
Pancreatic insufficiency, n (%) | 176 (76.19) | 13 (100) | 0.04 |
Combined liposoluble vitamins supplementation, n (%) | 172 (74.46) | 13 (100) | 0.04 |
Isolated VD supplementation, n (%) | 42 (18.18) | 0 (0) | 0.13 |
VD dose, IU/d Median (IQR) | 4800 (3000–8000) (n = 213) | 4000 (2500–6500) | 0.43 |
